Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and/or Refractory CD33+ AML”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Post-approval studies (Phase 4)Study completedNCT03727750
What this trial is testing

Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

Who this might be right for
ECGPharmacokineticsSafety
Pfizer 51
Early research (Phase 1)Looking for participantsNCT06419634
What this trial is testing

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Bristol-Myers Squibb 105
Early research (Phase 1)Looking for participantsNCT06367673
What this trial is testing

Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia

Who this might be right for
AML, Adult
Zhejiang University 24
Early research (Phase 1)Looking for participantsNCT05945849
What this trial is testing

CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML

Who this might be right for
Leukemia, Myeloid, Acute
University of Pennsylvania 16
Early research (Phase 1)Study completedNCT04070768
What this trial is testing

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Who this might be right for
Acute Myeloid Leukemia
John Quigley 18
Not applicableNo Longer AvailableNCT02312037
What this trial is testing

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

Who this might be right for
CD33 Positive Acute Myelogenous Leukemia
Pfizer
Testing effectiveness (Phase 2)UnknownNCT02944162
What this trial is testing

CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML

Who this might be right for
Acute Myelogenous LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia With Maturation+2 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Very early researchUnknownNCT03795779
What this trial is testing

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes+2 more
iCell Gene Therapeutics 20
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Large-scale testing (Phase 3)UnknownNCT00006045
What this trial is testing

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Who this might be right for
Leukemia
Facet Biotech
Early research (Phase 1)Study completedNCT04207190
What this trial is testing

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Roswell Park Cancer Institute 24
Early research (Phase 1)Study completedNCT03144245
What this trial is testing

Study of AMV564 in Patients With AML

Who this might be right for
Acute Myeloid Leukemia
Amphivena Therapeutics, Inc. 53
Early research (Phase 1)Looking for participantsNCT05672147
What this trial is testing

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia+1 more
City of Hope Medical Center 27
Early research (Phase 1)UnknownNCT05445765
What this trial is testing

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

Who this might be right for
Relapsed and/or Refractory Acute Myeloid LeukemiaHigh Risk Hematologic Malignancies
iCell Gene Therapeutics 10
Early research (Phase 1)Study completedNCT03915379
What this trial is testing

JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Janssen Research & Development, LLC 68
Testing effectiveness (Phase 2)UnknownNCT01864902
What this trial is testing

Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33

Who this might be right for
Relapsed Adult Myeloid LeukemiaChemotherapy Refractory Adult Myeloid Leukemia
Chinese PLA General Hospital 10
Early research (Phase 1)Ended earlyNCT00543972
What this trial is testing

Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

Who this might be right for
Myeloid Leukemia
Sanofi 12
Testing effectiveness (Phase 2)Study completedNCT03390296
What this trial is testing

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center 50
Early research (Phase 1)WithdrawnNCT05248685
What this trial is testing

Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Beijing Boren Hospital
Early research (Phase 1)Active Not RecruitingNCT03927261
What this trial is testing

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Precigen, Inc 88
Load More Results